FCM
EIDX

Flinton Capital Management’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Flinton Capital Management’s Portfolio EIDX Stock Details EIDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-3,230
Closed -$100K – 919
2019
Q2 		$100K Hold
3,230
– – ﹤0.01% 778
2019
Q1 		$76K Hold
3,230
– – ﹤0.01% 790
2018
Q4 		$44K Sell
3,230
-11,730
-78% -$148K ﹤0.01% 805
2018
Q3 		$149K Buy
14,960
+9,554
+177% +$157K ﹤0.01% 747
2018
Q2 		$110K Buy
+5,406
New +$113K ﹤0.01% 753

Other funds holding EIDX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Flinton Capital Management's EIDX Position: Q3 2019 in Review

Flinton Capital Management sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q3 2019, closing a stake of 3,230 shares — an estimated $100K sold.

Flinton Capital Management first reported a position in EIDX in Q2 2018 and held it in 5 quarters. The position peaked at $149K in Q3 2018. 79 funds tracked by Wall St. Rank hold EIDX as of Q3 2019.

  • Flinton Capital Management reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q3 2019 after selling out during the quarter.
  • Flinton Capital Management sold 3,230 Eidos Therapeutics, Inc. Common Stock shares in Q3 2019, an estimated $100K.
  • Flinton Capital Management first reported a position in Eidos Therapeutics, Inc. Common Stock in Q2 2018 and held it in 5 quarters.
  • Flinton Capital Management's Eidos Therapeutics, Inc. Common Stock position peaked at $149K in Q3 2018.
  • 79 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q3 2019.

Based on Flinton Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.